GlassScriptPhysician profile
Paul M Perry
NPI 1689614513
$13,390.99
in general payments reported to CMS, 2019-2025
48 companies · $2,223 in 2025
The $2,223 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,405 · 2020: $626 · 2021: $1,238 · 2022: $2,293 · 2023: $2,013 · 2024: $2,593 · 2025: $2,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,829.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,246.26 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,889.69 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,295.63 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Insmed, INC. | $767.00 | 2019-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $757.58 | 2020-2025 | Wakix |
| Genzyme Corporation | $463.33 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $453.33 | 2021-2025 | Dupixent |
| Genentech USA, INC. | $439.42 | 2019-2025 | Xolair |
| United Therapeutics Corporation | $413.69 | 2019-2025 | Tyvaso, Tyvaso |
| Merck Sharp & Dohme LLC | $364.49 | 2019-2025 | Zerbaxa, Recarbrio, Keytruda |
| Jazz Pharmaceuticals INC. | $336.77 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $317.68 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $293.72 | 2020-2025 | Acthar |
| Mylan Specialty L.P. | $285.90 | 2019-2024 | Yupelri |
| Electromed, INC. | $279.84 | 2024-2025 | Smartvest |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $259.37 | 2022-2025 | Glassia |
| Bayer Healthcare Pharmaceuticals INC. | $239.13 | 2019-2024 | |
| La Jolla Pharmaceutical Company | $206.65 | 2019-2024 | Giapreza |
| Actelion Pharmaceuticals US, INC. | $196.64 | 2019-2024 | Opsumit, Uptravi |
| Ani Pharmaceuticals, INC. | $177.90 | 2023-2025 | Purified Cortrophin Gel |
| Tetraphase Pharmaceuticals, INC. | $148.18 | 2019-2020 | |
| Intuitive Surgical, INC. | $134.22 | 2022 | |
| Sunovion Pharmaceuticals INC. | $127.31 | 2019 | |
| Amgen INC. | $116.62 | 2022-2025 | Tezspire |
| Pulmonx Corporation | $113.28 | 2019-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Portola Pharmaceuticals, LLC | $106.33 | 2019-2020 | |
| Abiomed | $103.49 | 2020 | |
| Philips North America LLC | $86.27 | 2019-2024 | (Ak6) Vest Therapy |
| Gilead Sciences, INC. | $73.43 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $67.47 | 2019 | |
| Body Vision Medical INC. | $66.86 | 2024 | Lungvision |
| Veran Medical Technologies, INC. | $60.20 | 2019 | |
| Astellas Pharma US INC | $53.47 | 2019 | |
| Grifols USA, LLC | $51.44 | 2019-2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $50.08 | 2025 | Yupelri |
| Medtronic, INC. | $44.00 | 2023 | Illumisite |
| Verona Pharma, INC. | $40.41 | 2025 | Ohtuvayre |
| Fisher & Paykel Healthcare INC | $38.80 | 2025 | Fisher & Paykel Healthcare |
| Pfizer INC. | $34.45 | 2022-2024 | |
| 3b Medical, INC. | $31.86 | 2024-2025 | Luna |
| Baxter Healthcare | $31.07 | 2024-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Axsome Therapeutics, INC. | $27.81 | 2023-2024 | Sunosi |
| Shionogi INC | $24.20 | 2022 | |
| Chiesi USA, INC. | $23.17 | 2019 | |
| Ambu INC. | $18.88 | 2022 | |
| Aerin Medical INC. | $16.74 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2021 | |
| Breas Medical, INC. | $3.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.